Prophase Labs (PRPH) 1.32 $PRPH
ProPhase Labs, Inc. CEO & Chairman Ted William Karkus to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 11, 2014
Marketwired - Thu Dec 11, 6:15AM CST
ProPhase Labs, Inc. (NASDAQ: PRPH), a company that engages in the manufacture, marketing, and distribution of homeopathic and health products to the general public, announced today that CEO & Chairman Ted William Karkus will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's The Traders Network Show. In this exclusive 2-segment interview, Mr. Karkus will discuss the research and development of over-the-counter (OTC) drugs, natural base health products with supplements, personal care and cosmeceutical products. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
PRPH: 1.32 (-0.03)
ProPhase Labs reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:48AM CST
PRPH: 1.32 (-0.03)
ProPhase Labs Reports Financial Results for the Three and Nine Months Ended September 30, 2014
Marketwired - Thu Nov 13, 7:31AM CST
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $5.1 million for the three months ended September 30, 2014 as compared to net sales of $5.9 for the three months ended September 30, 2013. During the three months ended September 30, 2014, the Company recorded a $3.6 million non-cash charge to operations ("Impairment Charge"
for the impairment of its intangible asset, licensed technology related to its Phusion Labs joint venture. The Company realized a net loss, inclusive of the Impairment Charge, for the three months ended September 30, 2014, of $3.2 million, or ($0.18) per share, compared to net income of $1.2 million, or $0.08 per share, for the three months ended September 30, 2013.
PRPH: 1.32 (-0.03)
ProPhase anticipates USD3.6m impairment charge in the Q3 fiscal 2014
M2 - Thu Sep 11, 7:51AM CDT
Medical science company ProPhase Labs (NASDAQ
RPH) said on Wednesday that it expects to report a USD3.6m charge for the impairment of its intangible asset, certain licensed technology related to its Phusion Laboratories joint venture during the third quarter of fiscal 2014.
PRPH: 1.32 (-0.03)
ProPhase Expects to Report a $3.6 Million Impairment Charge Relating to Its Phusion Joint Venture
Marketwire - Wed Sep 10, 3:16PM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today it will likely report a $3.6 million charge for the impairment of the Company's intangible asset, certain licensed technology, related to its Phusion Laboratories, LLC ("Phusion" joint venture during the third quarter of fiscal 2014.
PRPH: 1.32 (-0.03)
ProPhase Finalizes Resolution of Long-Standing Litigations
Marketwire - Wed Sep 10, 3:10PM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today the Company has consummated a definitive, global Settlement Agreement ("Settlement Agreement" resolving all of its litigation with certain of the Company's former managers and with certain shareholders. The cases that have been settled include ProPhase Labs, Inc. v. Quigley, et al., Court of Common Pleas of Bucks County, Pennsylvania, Civ. A. No. 2010-08227; ProPhase Labs, Inc. v. Quigley, et al., Court of Common Pleas of Bucks County, Pennsylvania, Civ. A. No. 2011-09815; the appeal filed by the plaintiff in the matter Quigley v. ProPhase Labs. Inc.'s Officers and Directors, el al, Court of Common Pleas of Philadelphia County, December Term, 2011, No. 111200409; together with certain ancillary litigation.
PRPH: 1.32 (-0.03)
ProPhase Labs posts higher net loss of USD3.1m for three months ended 30 June 2014
M2 - Wed Aug 13, 7:52AM CDT
Medical science company ProPhase Labs (NASDAQRPH) disclosed on Tuesday its net loss of USD3.1m (USD0.19 per share) for the three months ended 30 June 2014.
PRPH: 1.32 (-0.03)
ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2014
Marketwire - Tue Aug 12, 7:02AM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $1.8 million for the three months ended June 30, 2014 as compared to net sales of $1.9 million for the three months ended June 30, 2013. The Company realized a net loss for the three months ended June 30, 2014, of $3.1 million, or ($0.19) per share, compared to a net loss of $1.7 million, or ($0.11) per share, for the three months ended June 30, 2013.
PRPH: 1.32 (-0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Jun 24, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
RIVR: 21.77 (+0.27), PRPH: 1.32 (-0.03), VRTX: 131.00 (-3.25), CENT: 10.28 (+0.19), NURO: 1.73 (unch), PLXT: 6.50 (+0.02), PRKR: 0.86 (-0.01), CENTA: 10.94 (+0.05), MSBF: 11.50 (+0.38), UCBA: 12.51 (+0.27), MCRS: 67.99 (unch), NSPH: 0.25 (-0.01)
ProPhase Labs, Inc. CEO & Chairman Ted William Karkus to Be Interviewed on Clear Channel - iHeart Business Talk Radio's "The Trader's Network" on December 11, 2014
Marketwired - Thu Dec 11, 6:15AM CST
ProPhase Labs, Inc. (NASDAQ: PRPH), a company that engages in the manufacture, marketing, and distribution of homeopathic and health products to the general public, announced today that CEO & Chairman Ted William Karkus will be interviewed live by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's The Traders Network Show. In this exclusive 2-segment interview, Mr. Karkus will discuss the research and development of over-the-counter (OTC) drugs, natural base health products with supplements, personal care and cosmeceutical products. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
PRPH: 1.32 (-0.03)
ProPhase Labs reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:48AM CST
PRPH: 1.32 (-0.03)
ProPhase Labs Reports Financial Results for the Three and Nine Months Ended September 30, 2014
Marketwired - Thu Nov 13, 7:31AM CST
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $5.1 million for the three months ended September 30, 2014 as compared to net sales of $5.9 for the three months ended September 30, 2013. During the three months ended September 30, 2014, the Company recorded a $3.6 million non-cash charge to operations ("Impairment Charge"
for the impairment of its intangible asset, licensed technology related to its Phusion Labs joint venture. The Company realized a net loss, inclusive of the Impairment Charge, for the three months ended September 30, 2014, of $3.2 million, or ($0.18) per share, compared to net income of $1.2 million, or $0.08 per share, for the three months ended September 30, 2013. PRPH: 1.32 (-0.03)
ProPhase anticipates USD3.6m impairment charge in the Q3 fiscal 2014
M2 - Thu Sep 11, 7:51AM CDT
Medical science company ProPhase Labs (NASDAQ
RPH) said on Wednesday that it expects to report a USD3.6m charge for the impairment of its intangible asset, certain licensed technology related to its Phusion Laboratories joint venture during the third quarter of fiscal 2014. PRPH: 1.32 (-0.03)
ProPhase Expects to Report a $3.6 Million Impairment Charge Relating to Its Phusion Joint Venture
Marketwire - Wed Sep 10, 3:16PM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today it will likely report a $3.6 million charge for the impairment of the Company's intangible asset, certain licensed technology, related to its Phusion Laboratories, LLC ("Phusion"
joint venture during the third quarter of fiscal 2014. PRPH: 1.32 (-0.03)
ProPhase Finalizes Resolution of Long-Standing Litigations
Marketwire - Wed Sep 10, 3:10PM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) announced today the Company has consummated a definitive, global Settlement Agreement ("Settlement Agreement"
resolving all of its litigation with certain of the Company's former managers and with certain shareholders. The cases that have been settled include ProPhase Labs, Inc. v. Quigley, et al., Court of Common Pleas of Bucks County, Pennsylvania, Civ. A. No. 2010-08227; ProPhase Labs, Inc. v. Quigley, et al., Court of Common Pleas of Bucks County, Pennsylvania, Civ. A. No. 2011-09815; the appeal filed by the plaintiff in the matter Quigley v. ProPhase Labs. Inc.'s Officers and Directors, el al, Court of Common Pleas of Philadelphia County, December Term, 2011, No. 111200409; together with certain ancillary litigation. PRPH: 1.32 (-0.03)
ProPhase Labs posts higher net loss of USD3.1m for three months ended 30 June 2014
M2 - Wed Aug 13, 7:52AM CDT
Medical science company ProPhase Labs (NASDAQ
RPH) disclosed on Tuesday its net loss of USD3.1m (USD0.19 per share) for the three months ended 30 June 2014. PRPH: 1.32 (-0.03)
ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2014
Marketwire - Tue Aug 12, 7:02AM CDT
ProPhase Labs, Inc. (NASDAQ: PRPH) (www.ProPhaseLabs.com) today reported its net sales were $1.8 million for the three months ended June 30, 2014 as compared to net sales of $1.9 million for the three months ended June 30, 2013. The Company realized a net loss for the three months ended June 30, 2014, of $3.1 million, or ($0.19) per share, compared to a net loss of $1.7 million, or ($0.11) per share, for the three months ended June 30, 2013.
PRPH: 1.32 (-0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Jun 24, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
RIVR: 21.77 (+0.27), PRPH: 1.32 (-0.03), VRTX: 131.00 (-3.25), CENT: 10.28 (+0.19), NURO: 1.73 (unch), PLXT: 6.50 (+0.02), PRKR: 0.86 (-0.01), CENTA: 10.94 (+0.05), MSBF: 11.50 (+0.38), UCBA: 12.51 (+0.27), MCRS: 67.99 (unch), NSPH: 0.25 (-0.01)
